Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts in the RA therapeutic landscape has occurred with the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). There are five classes of bDMARDs currently available, each with a different molecular target and subtle differences in their efficacy and safety profile. This review also describes the "real-world" use of bDMARDs and how they fit into the overall RA treatment guidelines.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370108 | PMC |
| http://dx.doi.org/10.2147/BTT.S252575 | DOI Listing |
Publication Analysis
Top Keywords
rheumatoid arthritis
8
biological therapies
4
therapies rheumatoid
4
arthritis overview
4
overview clinician
4
clinician rheumatoid
4
arthritis disease
4
disease characterised
4
characterised inflammation
4
inflammation synovial
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!